109 completed, 6 terminated, 5 unknown, 4 recruiting. 128 Phase 3, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 128 | Completed 109, Terminated 6, Unknown 5, Recruiting 4, Withdrawn 4 |
| Phase 2 | 16 | Completed 13, Withdrawn 2, Unknown 1 |
Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy REGN-2Cat, Freneslerbart, Mevonlerbart - Allergic Conjunctivitis | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 570 | 2026-07-31 | 2026-11-05 |
| An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED Cenegermin, Vehicle - Persistent Corneal Epithelial Defect | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 150 | 2026-06-02 | 2026-10-07 |
| 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion, 0.1% Cyclosporin A cationic ophthalmic emulsion - Vernal Keratoconjunctivitis | Phase 3 | Recruiting | The University of Hong Kong | 94 | 2026-02-09 | 2026-11-09 |
| Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Terminated | Regeneron Pharmaceuticals | 24 | 2026-01-10 | 2026-09-01 |
| Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis Fusidic Acid 1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Recruiting | Baxis Pharmaceuticals, Inc. | 400 | 2025-03-21 | 2026-03-17 |
| A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 54 | 2024-11-19 | 2026-04-21 |
| A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy REGN1908, REGN1909, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 64 | 2024-11-06 | 2026-05-08 |
| Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops - Dry Eye Disease (DED) | Phase 3 | Completed | Jadran Galenski laboratorij d.d. | 86 | 2024-03-20 | 2025-07-03 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 512 | 2023-04-20 | 2025-07-10 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035% - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 188 | 2022-10-12 | 2025-02-14 |
| Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye Vizol S LIPID BALANCE eye drops, ophthalmic saline eye drops - Dry Eye Disease | Phase 3 | Completed | Jadran Galenski laboratorij d.d. | 64 | 2022-06-01 | 2024-03-21 |
| Safety Study of Tivanisiran to Treat Dry Eye Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Disease | Phase 3 | Completed | Sylentis, S.A. | 301 | 2022-03-24 | 2026-09-09 |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 131 | 2022-01-21 | 2026-05-14 |
| A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat REGN1908-1909, Matching Placebo - Allergic Rhinitis Due to Cat Allergy | Phase 3 | Terminated | Regeneron Pharmaceuticals | 446 | 2021-07-30 | 2024-06-11 |
| Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Disease, Sjögren Syndrome | Phase 3 | Completed | Sylentis, S.A. | 203 | 2021-05-25 | 2024-02-20 |
| Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children Bilastine, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Faes Farma, S.A. | 59 | 2021-03-26 | 2023-03-16 |
| Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis REGN5713, REGN5714, REGN5715 - Allergic Rhinitis, Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 353 | 2021-01-14 | 2022-10-27 |
| Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 610 | 2019-12-20 | 2022-01-19 |
| The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 95 | 2019-12-05 | 2024-11-20 |
| A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber Sublingual allergy immunological tablet, Placebo - Allergic Rhinoconjunctivitis | Phase 3 | Terminated | ALK-Abelló A/S | 80 | 2019-11-04 | 2022-06-30 |
Showing 20 of 128. Sign in to see all of them.
Conjunctivitis, Allergic (65) · Dry Eye Syndromes (25) · Keratoconjunctivitis Sicca (23) · Conjunctivitis, Bacterial (20) · Hypersensitivity (8) · Rhinitis, Allergic (6) · Rhinitis (5) · Rhinitis, Allergic, Seasonal (5) · Eye Infections (4) · Keratitis (4) · Keratoconjunctivitis (4) · Trachoma (4) · Blepharitis (3) · Sjogren's Syndrome (3)
Eye Diseases (127) · Conjunctival Diseases (126) · Immune System Diseases (75) · Hypersensitivity, Immediate (68) · Hypersensitivity (64) · Corneal Diseases (33) · Infections (33) · Keratitis (26) · Bacterial Infections and Mycoses (25) · Lacrimal Apparatus Diseases (25) · Bacterial Infections (24) · Eye Infections (24) · Eye Infections, Bacterial (23) · Keratoconjunctivitis (23)
Olopatadine Hydrochloride (11) · Ophthalmic Solutions (9) · Azithromycin (8) · Ketotifen (7) · Dexamethasone (4) · Gatifloxacin (4) · besifloxacin (4) · Loteprednol Etabonate (3) · Lubricant Eye Drops (3) · Moxifloxacin (3) · Tacrolimus (3) · bepotastine besilate (3) · Albuterol (2) · Brimonidine Tartrate (2) · Cyclosporine (2)
Bausch & Lomb Incorporated (15) · Alcon Research (11) · Vistakon Pharmaceuticals (9) · Allergan (7) · ALK-Abelló A/S (6) · Regeneron Pharmaceuticals (6) · Aciex Therapeutics, Inc. (4) · Aldeyra Therapeutics, Inc. (3) · Merck Sharp & Dohme LLC (3) · Mimetogen Pharmaceuticals USA, Inc. (3) · Sun Pharmaceutical Industries Limited (3) · Adapt Produtos Oftalmológicos Ltda. (2) · Astellas Pharma Inc (2) · Campus Bio-Medico University (2) · Faes Farma, S.A. (2)
United States (67) · Germany (9) · Canada (8) · Japan (8) · France (7) · Spain (7) · Italy (6) · Poland (6) · Brazil (5) · India (4) · Israel (4) · Austria (3) · Belgium (3) · Czechia (3) · Hungary (3)
Brian Pall, OD, MS, FAAO (4) · Abhijit Narvekar, MS, MBBS (2) · Edward Meier, MD (2) · Gail L Torkildsen, MD (2) · Garth Cumberlidge, PhD (2) · Ingerman Avner, MD (2) · Johnson Varughese (2) · Jon Williams, PhD (2) · Lawrence T Friedhoff, MD, PhD (2) · Stacey Ackerman, MD (2)
PMID 25685162, PMID 21681652, PMID 22991696, PMID 24836393, PMID 25788949, PMID 26507708, PMID 27466061, PMID 17652708, PMID 18374301, PMID 18595980, PMID 19843481, PMID 20488431, PMID 20642205, PMID 21211642, PMID 21211643, PMID 21250860, PMID 21397770, PMID 21771118, PMID 22093109, PMID 22256909, PMID 22420526, PMID 22644963, PMID 23622121, PMID 23706715, PMID 24289915, PMID 24468255, PMID 24517417, PMID 25163405, PMID 25244402, PMID 25473263, PMID 26266427, PMID 26507709, PMID 27445067, PMID 28736342, PMID 28736344, PMID 30326954, PMID 30472801, PMID 33469259, PMID 33619183, PMID 34857814, PMID 34919861, PMID 36729473, PMID 36811846, PMID 37438187, PMID 37872059, PMID 38105911, PMID 38134305, PMID 38687061, PMID 38991011, PMID 39328900
2008 (2), 2016 (2), 2018 (1), 2025 (1), K23EY019881 (1), R34EY017626 (1), U10EY023939 (1)